The Use of Technical Vessel Sealing Devices for Recipient Hepatectomy in Liver Transplantation (SEALIVE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03323242|
Recruitment Status : Not yet recruiting
First Posted : October 26, 2017
Last Update Posted : July 13, 2018
|Condition or disease||Intervention/treatment||Phase|
|Hepatectomy||Device: LigaSure Device: Harmonic Ultrasonic dissector||Not Applicable|
Liver transplantation (LT) is a well-established procedure for the treatment of end stage liver disease. Many improvements in the surgical technique rendered this operation relatively safe. Most important operative innovations after the initial introduction of LT in the clinical Routine undertaken by Starzl include the use of veno-venous bypass in LT, the piggy-back technique with preservation of the recipients' caval vein and it's modification which was introduced by Belghiti with side-to-side cavo-caval anastomosis. Nevertheless very few improvements have been introduced in the surgical technique with regards to tissue preparation and sealing the blood vessels during recipient hepatectomy. Due to end stage liver disease and both the recipients' general and coagulatory condition, the hepatectomy carries the risk of severe blood loss which can impair the outcome after LT. Usually the recipient hepatectomy is carried out as a combination of sharp dissection of the hepatic adhesions to the abdominal wall and the diaphragm and clip or suture ligature of small retrohepatic caval vein branches.
With advances in surgical procedures and equipment, modern technologies have been introduced, which have shortened operation time and improved surgical outcomes. Exquisite equipment for liver parenchyma transection, such as Cavitron ultrasonic surgical aspirator, ultrasonic dissector (USD), LigaSure (LS) and Tissue Link can also be used to reduce hemorrhage in liver resection. The ultrasonic scalpel (Ethicon) is a new USD that cuts and coagulates tissue using ultrasound at frequencies higher than those used by an ultrasonic aspirator. This device can also serve as a grasper and basically utilizes a blade which oscillates at 55 kHz, thus producing heat and enabling coagulation of vessels. Recently, its use and potential advantages in open liver resection have been demonstrated. The main technical advancement in this field relates to decreased intra-operative bleeding. Results of using USD (Harmonic Scalpel) during recipient hepatectomy showed that this method is safe compared with conventional knot tying ligation regarding intra- and postoperative bleeding rate. The electrothermal bipolar vessel sealing device LS is another alternative, which applies electrothermal bipolar coagulation and dissection in one step. The LS dissection device seals the tissue first before it is divided (both Tasks are performed with the same device). This may prevent severe bleeding. Furthermore, the sealing device is capable of coping with the small liver veins which can be sealed and divided safely without the need for sutures or clips. Especially the latter of which is known for interfering with sufficient "tangential" clamping of the inferior caval vein (IVC) for side to side cavo-cavostomy during piggy-back LT. It was reported that the use of LS devices for recipient hepatectomy in LT. It was concluded that, LS vessel sealing was an efficient method and that vessel sealing of the caval and Portal veins as well as other structures could be safely performed in the setting of end-stage liver disease.
To our knowledge, no randomized clinical trial has been conducted to compare various innovative dissection methods against the standard techniques used for recipient hepatectomy. While LS and USD have been proven to be used safely in several major surgical procedures, including liver resection, their ability to reduce blood loss in liver transplant recipient hepatectomy has not yet been evaluated systematically.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||69 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Masking Description:||Blinding the surgical staff is impossible due to the use of different methods in the three groups under investigation. Since the primary endpoint "total blood loss" will be precisely recorded during surgery by independent staff and secondary endpoints are objective physiological findings, blinding the subjects is not needed. Therefore, the open design is not expected to cause any avoidable bias.|
|Official Title:||-SEALIVE- The Use of Technical Vessel Sealing Devices for Recipient Hepatectomy in Liver Transplantation: Study Protocol for a Randomized Controlled Trial|
|Estimated Study Start Date :||August 1, 2018|
|Estimated Primary Completion Date :||July 1, 2021|
|Estimated Study Completion Date :||September 1, 2021|
No Intervention: Control group
Recipient hepatectomy using conventional bipolar coagulation devices, surgical suture ligatures, and surgical clips (or any dissecting / coagulating device other than LS)
Experimental: LS group
Recipient hepatectomy applying LigaSure.
The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
Experimental: USD group
Recipient hepatectomy applying Harmonic Ultrasonic dissector.
Device: Harmonic Ultrasonic dissector
The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
- Total Blood loss during surgical procedure [ Time Frame: One day ]
The suction container fluid volume (in 20 milliliters) will be added to the weight (in grams) of all surgical swabs at the end of skin closure procedures (A). The difference of the density of the rinse solution (isotonic Sodium Chloride solution) and blood is approximately 0.055 g/cm³. Regarding the accuracy of these measurements, this difference is clinically irrelevant.
The volume of the entire rinse fluid (in milliliters) that is used during the procedure and the amount of ascites (in milliliters) will be added to the known dry weight (in grams) of the respective number of surgical swabs that are used during the procedure and the known dry weight of the drip catching swab container (B).
The total blood loss is defined as "A" minus "B" in milliliters.
- Blood loss during recipient hepatectomy [ Time Frame: One day ]
- Time from skin incision to end of hemostasis after hepatectomy [ Time Frame: One day ]
- Time from skin incision to end of skin closure [ Time Frame: One day ]
- Hemodynamic status during surgery [ Time Frame: One day ]Data on the mean arterial pressure and central venous pressure will be obtained at the beginning of hepatectomy after incision and adhesiolysis.
- The number of packed red blood cells (PRBC) units transfused during surgery [ Time Frame: One day ]
- The number of fresh frozen plasma (FFP) units transfused during surgery [ Time Frame: One day ]
- The number of platelet units transfused during surgery [ Time Frame: One day ]
- Conversion rate [ Time Frame: One day ]Conversion rate to alternative methods during recipient hepatectomy in LS and USD groups
- Coagulation state [ Time Frame: Ten days ]International Normalized Ratio, partial thromboplastin time and platelet levels of patients will be recorded pre- and postoperatively until POD 10.
- Hemoglobin level [ Time Frame: Ten days ]Hemoglobin Levels of patients will be recorded pre- and postoperatively until POD 10.
- Postoperative PRBC and FFP Transfusion until POD 10 [ Time Frame: Ten days ]
- Postoperative bleeding [ Time Frame: Ten days ]Postoperative hemorrhaging until POD 10 will be recorded and classified according to the Clavien-Dindo classification.
- Postoperative morbidity [ Time Frame: Three months ]Postoperative morbidity will be recorded and classified according to the Clavien-Dindo classification.
- Retransplantation rate [ Time Frame: Three months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03323242
|Contact: Philipp Houben, MD||+4962215636974||Philipp.Houben@med.uni-heidelberg.de|
|Principal Investigator:||Philipp Houben, MD||Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Germany|